Correlation of HIV-1 drug resistant mutations and virologic failure.
PMID: 34584606
2021
The Pan African medical journal
Abstract: Out of 17 new mutations, 14 resulted in virologic failure and included NRTIs (L74I, L74V, T69D, V65R);
Result: Most of the new mutations also encoded for resistance to prescribed drugs and these included L74I/V, T69D, V65R as NRTIs; A98G, V179E/F/D/F as NNRTs and I54V, F53L, L89T, G48A, K20T as PIs.
Table: L74I
Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone.
Result: The most prevalent RT RAMs among children and adolescents and their relative proportions were as follows: M184V (76.6%, n = 49/64), K103N (45.3%, n = 29/64), Y181C/V/I (28.1%, n = 18/64), T215F/Y (25.0%, n = 16/64), V108I (18.8%, n = 12/64), A98G (15.6%, n = 10/64), G190A (12.5%, n = 8), K101E/H (12.5%, n = 8), M41L (10.9%, n = 7/64), L74I/V (10.9%, n = 7/64), and H221Y (10.9%, n = 7/64) (Figure 1a,b).
High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
PMID: 34453542
2021
The Journal of antimicrobial chemotherapy
Abstract: RESULTS: HIV-1 IN-recombinant viruses harbouring single primary mutations (N155H or Y143R/S) or in combination with secondary INSTI mutations (T97A, M50I, L74IM, E157Q, G163R or V151I) were susceptible to both bictegravir and cabotegravir.
HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.
Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy.
PMID: 34189182
2021
Open forum infectious diseases
Conclusion: A pretreatment genotype, which included INI testing, revealed an HIV-1 subtype B along with an L74I (RT) mutation conferring high-level resistance to didanosine and intermediate-level resistance to abacavir.
Conclusion: A repeat viral load was 98 000 copies/mL, and an updated genotype revealed an M184V (RT) mutation conferring resistance to lamivudine and FTC in addition to the previously seen L74I (RT) mutation.
Conclusion: At follow-up the next month (week 37), he had an HIV RNA load of 14 095 copies/mL and a newly acquired R263K mutation (conferring low-level resistance to BIC) along with the previously documented M184V (RT
Transmitted HIV drug resistance and subtype patterns among blood donors in Poland.
Abstract: Additionally, E157Q polymorphism was observed in 9.8% and L74I in 11.5% of integrase sequences.
Result: Additionally, we have analyzed the distribution of the L74I polymorphism which was observed in 20 (11.5%) of the integrase sequences, being more prevalent in subtype A samples (n = 16, 94.1%) compared to 2.6% (n = 4) in subtype B (p < 0.0001) (supplemental table 3.
Result: As L74I variant was present in virtually all A6 sequences it was also observed within the identified clusters.
Discussion: Furthermore, L74I polymorphism was almost invariably (94.1%) present in A6 sequences.
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Abstract: As expected, discriminatory DRMs such as K65R, L74I, and Y115F were noted in Tenofovir (TDF) containing regimens while the Thymidine Analogue Mutations (TAMs) L210W and T215 mutations were in Zi
Result: K65R (95.2%, p = 0.00005), Y115F (85%, p = 0.005) and L74I (82.6%, p= 0.005) mutations appeared more in the TDF/3TC/EFV group as compared to AZT/3TC/EFV group.
Result: However, comparisons for individual mutations within the NRTI class of drugs indicated that mutations K65R, L74I, Y115F, L210W and T215 mutations differed significantly among the two regimens.
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Discussion: According to our findings, the frequency of the substitution Q148+ >=1 secondary mutation(s) (G140A/C/S, L74I or E138A/K/T) was 12%.
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Discussion: Other mutations detected in this study, which have been shown to confer resistance to NRTIs, were M184I, T69N, L74I, M41L, K70R/E, T215Y/F, and K219E.
Discussion: The presence of the L74I mutation in combination with the M184 V causes high-level resistance to both Abacavir and Didanosine.
Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
PMID: 32106437
2020
International journal of molecular sciences
Abstract: Integrase polymorphic and accessory RAMs found included T97A, E157Q, A128T, M50I, S119R, L74M, L74I, S230N, and E138D (0.3%-23.5% of samples).
Result: Four other mutations were identified in cohort samples: M50I (in 6 samples), S119R (in 4 samples, all CRF02_AG), L74M (in 8 CRF02_AG and 1 CRF11_cpx samples), and L74I in 25 samples of which 22 (88%) were CRF02_AG (Table 2).
Result: Other mutations in database samples included M50I,
ViMRT
HIV mutation literature information.
PMID: 
2021
The Pan African medical journal
